Format

Send to

Choose Destination
Eur J Cancer Prev. 2015 Jul;24(4):340-2. doi: 10.1097/CEJ.0000000000000067.

Early effects of human papillomavirus vaccination in Belgium.

Author information

1
aInternational Centre for Reproductive Health (ICRH), Ghent University bDepartment of Obstetrics and Gynaecology, Ghent University Hospital, Ghent cSonic Health Care/AML, Antwerp dUnit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.

Abstract

Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.

PMID:
25117724
DOI:
10.1097/CEJ.0000000000000067
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center